AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19961044
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection lumbar plexus and sciatic nerve blocks
Trial: 18046188
Drug: Carbohydrate (CHO)
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (CHO) supplementation (20% maltodextrin at 0.6 g.kg FFM.h)
Trial: 15535402
Drug: HIV drug
RxNorm normalized name: HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV drug resistance testing
Trial: 31808598
Drug: Oral bambuterol
RxNorm normalized name: bambuterol
DrugBank: Bambuterol (DB01408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bambuterol hydrochloride (10 mg, once daily, for 3 days)
Trial: 31411184
Drug: Double antithrombotic
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double antithrombotic therapy (DT)
Trial: 31411184
Drug: Triple antithrombotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antithrombotic therapy (TT)
Trial: 25994179
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg biweekly (BIW)
Trial: 24861696
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg QW/QW
Trial: 24861696
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg BIW/QW
Trial: 22129348
Drug: Dietary protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary protein at 350 g/kg and lipid at 80 g/kg
Trial: 22129348
Drug: Dietary protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary protein at 300 g/kg and lipid at 60 g/kg
Trial: 22129348
Drug: Dietary lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary lipid at 80 g/kg
Trial: 19694385
Drug: Qianlie Beixi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qianlie Beixi Capsule
Trial: 19694385
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (compound tablets of zinc and protein)
Trial: 12720590
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Zn/d for 14 weeks followed by 3 mg Cu/d for 8 weeks
Trial: 10972662
Drug: Intravenous calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous calcitriol (1.5 mg/m2 body surface area)
Trial: 10972662
Drug: Oral calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcitriol (1.5 mg/m2 body surface area)
Trial: 10972662
Drug: Control values
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control values for Sr absorption (separate group of children with CRF)
Trial: 10972662
Drug: Intravenous calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous calcitriol and Oral calcitriol
Trial: 8439828
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nitrendipine initial dose
Trial: 8439828
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nitrendipine twice daily
Trial: 8439828
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nitrendipine once daily
Trial: 8439828
Drug: Chronic nitrendipine
RxNorm normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic nitrendipine therapy
Trial: 3301560
Drug: Flunarizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine (10 mg/die for patients <70 kg; 15 mg/die for patients >70 kg)
Trial: 30200895
Drug: Standard prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prednisolone plus high-dose mizoribine (10 mg/kg/day once daily for 2 years)
Trial: 11156638
Drug: Budesonide 6
RxNorm normalized name: budesonide 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 6 mg once daily
Trial: 10341672
Drug: Low-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat meal (0.2 g/kg body weight; mean 14 g)
Trial: 10341672
Drug: High-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat meal (0.6 g/kg body weight; mean 43 g)
Trial: 19670088
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose of 24 Gy
Trial: 19670088
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose of 27 Gy
Trial: 23014489
Drug: Whole-grain (WG)
RxNorm normalized name: rice (whole grain) allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-grain (WG) foods (80 g/d)
Trial: 23014489
Drug: Refined-grain (RG)
RxNorm normalized name: barley grain
DrugBank: Barley (DB10506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refined-grain (RG) foods (0 g/d)
Trial: 19954479
Drug: Rheopheresis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rheopheresis treatment (RT) twice a week for a total of ten treatments, along with high-dose supplementation of zinc and vitamins A, E, and beta-carotene.
Trial: 19954479
Drug: Rheopheresis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rheopheresis treatment (RT) after the fifth treatment.
Trial: 19954479
Drug: Rheopheresis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rheopheresis treatment (RT) compared to before RT at time 1 and time 2.
Trial: 17678776
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia with propofol target-controlled infusion
Trial: 17678776
Drug: Alfentanil with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil with propofol target-controlled infusion
Trial: 17678776
Drug: High-dose remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose remifentanil with propofol target-controlled infusion
Trial: 17678776
Drug: Low-dose remifentanil
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose remifentanil with propofol target-controlled infusion
Trial: 15181127
Drug: Dopamine agonist
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonist dosage in PD patients
Trial: 3481318
Drug: Ciprofloxacin 250
RxNorm normalized name: ciprofloxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 250 mg (twice daily)
Trial: 3481318
Drug: Enoxacin 400
RxNorm normalized name: enoxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxacin 400 mg (twice daily)
Trial: 3481318
Drug: Ofloxacin 200
RxNorm normalized name: ofloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 200 mg (twice daily)
Trial: 22342916
Drug: HBsAg-1018 ISS
RxNorm normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBsAg-1018 ISS vaccine
Trial: 22342916
Drug: Engerix-B(®) (licensed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engerix-B(®) (licensed hepatitis B vaccine)
Trial: 21047593
Drug: Serum PSA
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum PSA screening with a cut-off of 4 ng/ml
Trial: 21047593
Drug: Serum PSA
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum PSA screening with a cut-off of 3 ng/ml
Trial: 17548243
Drug: Sertraline 50
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50 mg once per day
Trial: 16262574
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment with exercise protocol for 10 sessions over 2 weeks.
Trial: 16262574
Drug: Placebo laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo laser treatment with exercise protocol for 10 sessions over 2 weeks.
Trial: 11905448
Drug: Dental auscultation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental auscultation and traditional oral health care education
Trial: 11905448
Drug: Traditional oral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional oral health care education
Trial: 10069683
Drug: Xamoterol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xamoterol (100 mg, p.o.)
Trial: 10069683
Drug: Xamoterol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xamoterol (200 mg, p.o.)
Trial: 10069683
Drug: Celiprolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (200 mg, p.o.)
Trial: 10069683
Drug: Celiprolol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (600 mg, p.o.)
Trial: 10069683
Drug: Celiprolol (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (1,200 mg, p.o.)
Trial: 10069683
Drug: Celiprolol (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (after terbutaline treatment)
Trial: 7567313
Drug: Ceftibuten suspension
RxNorm normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftibuten suspension (9 mg/kg once daily, max 400 mg)
Trial: 1967592
Drug: Intravenous fenoldopam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fenoldopam mesylate, infused at a maximal dose increment of 0.2 microgram/kg/min, with a maximal infusion rate of 1.5 micrograms/kg/min.
Trial: 1967592
Drug: Sodium nitroprusside,
RxNorm normalized name: Sodium Nitroprusside, 25 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium nitroprusside, infused at a maximal dose increment of 1 microgram/kg/min, with a maximal infusion rate of 8 micrograms/kg/min.
Trial: 7387812
Drug: Diazoxide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazoxide (300 mg i.v.) during untreated condition (n=29)
Trial: 7387812
Drug: Diazoxide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazoxide (300 mg i.v.) during treatment with propranolol (320 mg/day) (n=15)
Trial: 7387812
Drug: Diazoxide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazoxide (300 mg i.v.) during treatment with propranolol plus atropine (0.04 mg/kg) (n=12)
Trial: 7387812
Drug: Diazoxide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazoxide (300 mg i.v.) during propranolol (n=15)
Trial: 7387812
Drug: Diazoxide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazoxide (300 mg i.v.) without propranolol (n=15)
Trial: 7387812
Drug: Diazoxide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazoxide (300 mg i.v.) during propranolol plus atropine (n=12)
Trial: 25517261
Drug: Fentanyl transdermal
RxNorm normalized name: Fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl transdermal patch (Durogesic® D-TRANS)
Trial: 7848930
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine sulfate (MSO4) via continuous infusion (initial bolus of 0.03 mg/kg, infusion of 0.01% morphine at 5 mL/hour, titrated from 0.2 to 1.0 mg/hour)
Trial: 7848930
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine sulfate (MSO4) via intermittent bolus (initial bolus of 0.07 mg/kg, followed by 2-5 mg on demand)
Trial: 3907037
Drug: High fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fluid replacement (total volume of urine output + 30 ml/hr)
Trial: 3907037
Drug: Low fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fluid replacement (constant 125 ml/hr)
Trial: 24684771
Drug: PRT‐201 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRT‐201 at 10 μg
Trial: 24684771
Drug: PRT‐201 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRT‐201 at 30 μg
Trial: 24684771
Drug: PRT‐201 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRT‐201 at 10 μg (RCF subset)
Trial: 24684771
Drug: PRT‐201 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRT‐201 at 30 μg (RCF subset)
Trial: 22525444
Drug: Supplemental oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen (nasal prongs, 1-2 L/min flow)
Trial: 17663099
Drug: Drug-separated moxibustion
RxNorm normalized name: serrated swimming crab, cooked preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-separated moxibustion at the navel
Trial: 17663099
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (vitamin E capsules, 0.1 g twice daily)
Trial: 14997748
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors (Als)
Trial: 14997748
Drug: Neo-adjuvant endocrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo-adjuvant endocrine therapy
Trial: 14997748
Drug: Surrogate markers
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surrogate markers in neo-adjuvant endocrine treatment
Trial: 11126208
Drug: Caffeine/Ephedrine (CE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine/Ephedrine (CE) mixture (100 mg/10 mg for those <80 kg, 200 mg/20 mg for those >80 kg, taken three times daily)
Trial: 1571917
Drug: Single-dose TBI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose TBI (1000 cGy midplane, 800 cGy lungs) at HIGH dose rate (15 cGy/min)
Trial: 1571917
Drug: Single-dose TBI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose TBI (1000 cGy midplane, 800 cGy lungs) at LOW dose rate (6 cGy/min)
Trial: 1571917
Drug: Fractionated-dose TBI
RxNorm normalized name: Poliovirus, inactivated, fractional-dose (fIPV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated-dose TBI (1200 cGy midplane, 900 cGy lungs) at HIGH dose rate (6 cGy/min)
Trial: 1571917
Drug: Fractionated-dose TBI
RxNorm normalized name: Poliovirus, inactivated, fractional-dose (fIPV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated-dose TBI (1200 cGy midplane, 900 cGy lungs) at LOW dose rate (3 cGy/min)
Trial: 1571917
Drug: Single-dose HIGH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose HIGH instantaneous dose rate TBI
Trial: 30647034
Drug: Cardiac output-guided
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac output-guided fluid therapy with low-dose inotrope infusion
Trial: 24217699
Drug: Nitroxoline (NTX)
RxNorm normalized name: nitroxoline
DrugBank: Nitroxoline (DB01422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroxoline (NTX) at 250 mg
Trial: 24217699
Drug: Trimethoprim (TMP)
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimethoprim (TMP) at 200 mg
Trial: 24217699
Drug: Nitroxoline (NTX)
RxNorm normalized name: nitroxoline
DrugBank: Nitroxoline (DB01422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroxoline (NTX) at 250 mg three times a day
Trial: 11306208
Drug: Transdermal gel
RxNorm normalized name: Androgel 1% Transdermal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal gel (1.0 mg estradiol daily)
Trial: 10465378
Drug: Transdermal patch
RxNorm normalized name: TRANSDERMAL PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal patch (50 microg/24 h)
Trial: 9336557
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day of Panax ginseng C.A. Meyer (G115)
Trial: 9336557
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day of Panax ginseng C.A. Meyer (G115)
Trial: 26487588
Drug: Chemotherapy initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy initiation within 25 days post-surgery
Trial: 26487588
Drug: Chemotherapy initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy initiation after 25 days post-surgery
Trial: 24598777
Drug: Internet-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based treatment with email support by a urotherapist
Trial: 24598777
Drug: Postal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postal treatment program
Trial: 2173011
Drug: Joint alpha-
RxNorm normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joint alpha- and beta-adrenoreceptor pharmacological blocker
Trial: 31318648
Drug: Mesenchymal precursor
RxNorm normalized name: Allogeneic mesenchymal precursor cell
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal precursor cells as immunotherapy
Trial: 27808522
Drug: Reaching agreements
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reaching agreements on specific issues (e.g., custody, child support)
Trial: 25781193
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (2000 IUs daily for 3 months)
Trial: 19481320
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) vaccination (10 microg of vaccine every week for 8 weeks)
Trial: 19481320
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) vaccination (40 microg of vaccine at weeks 1 and 8)
Trial: 15109507
Drug: Topical clonazepam
RxNorm normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical clonazepam (1 mg tablet, sucked three times a day for 14 days)
Trial: 11295622
Drug: Daily dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dietary supplementation with selenium; dosage and duration not specified.
Trial: 9085968
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TA) 15 mg/kg IV followed by two additional doses of 10 mg/kg each
Trial: 8204940
Drug: IL2 as
RxNorm normalized name: DAB(SUB 389)IL2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL2 as a continuous infusion or high doses intravenous IL2 combined with alpha interferon (IFN) or a combination of IL2 and IFN as subcutaneous low doses
Trial: 8204940
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IL2 with Tumor Necrosis Factor (TNF) as rescue treatment
Trial: 25689245
Drug: Glargine insulin
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glargine insulin
Trial: 27091835
Drug: RI-in-PN (Regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RI-in-PN (Regular Insulin in Parenteral Nutrition)
Trial: 23642372
Drug: Focal laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focal laser photocoagulation plus intravitreal ranibizumab (L+R)
Trial: 23642372
Drug: Focal laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focal laser photocoagulation plus intravitreal bevacizumab (L+B)
Trial: 23642372
Drug: Focal laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focal laser photocoagulation (L)
Trial: 23642372
Drug: Focal laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focal laser photocoagulation plus intravitreal triamcinolone (L+T)
Trial: 21346758
Drug: Concurrent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent administration of oral deuterated alfentanil and intravenous unlabeled alfentanil
Trial: 21346758
Drug: Sequential dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential dosing of alfentanil
Trial: 21346758
Drug: Simultaneous dosing
RxNorm normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous dosing of alfentanil
Trial: 21346758
Drug: Rifampin, ketoconazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin, ketoconazole, and grapefruit juice (as inducers/inhibitors)
Trial: 19451297
Drug: Lopinavir-ritonavir (LPV/r)
RxNorm normalized name: lopinavir / ritonavir
DrugBank: Lopinavir (DB01601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lopinavir-ritonavir (LPV/r) monotherapy
Trial: 19451297
Drug: Lopinavir-ritonavir (LPV/r)
RxNorm normalized name: lopinavir / ritonavir
DrugBank: Lopinavir (DB01601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lopinavir-ritonavir (LPV/r) plus zidovudine and lamivudine triple therapy
Trial: 1563557
Drug: Intracervical application
RxNorm normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracervical application of highly viscous prostaglandin E2 (PGE2) gel